<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">Patient demographics and disease characteristics at baseline are shown in TableÂ 
 <xref rid="Tab1" ref-type="table">1</xref>. The BTH1677 and Control arms were similar with respect to age, sex, race, as well as time from initial tumor diagnosis to diagnosis of stage IIIB/IV NSCLC and diagnosis of stage IIIB/IV NSCLC to randomization. The percentage of patients with ECOG PS status of 1 vs 0 was higher in the BTH1677 arm (47.5%) than in the Control arm (33.3%). The percentage of patients who received prior cancer treatments (radiotherapy, surgery, chemotherapy, hormonal, or other) was also higher in the BTH1677 arm compared with the Control arm.
</p>
